FY2025 Earnings Forecast for BrainsWay Ltd. Issued By Northland Capmk (NASDAQ:BWAY)

BrainsWay Ltd. (NASDAQ:BWAY) – Research analysts at Northland Capmk issued their FY2025 EPS estimates for shares of BrainsWay in a note issued to investors on Tuesday, August 6th. Northland Capmk analyst C. Byrnes anticipates that the company will post earnings per share of $0.08 for the year. The consensus estimate for BrainsWay’s current full-year earnings is $0.02 per share.

A number of other analysts have also recently issued reports on the stock. HC Wainwright lifted their target price on shares of BrainsWay from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday. Northland Securities upped their price objective on shares of BrainsWay from $9.00 to $11.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Oppenheimer increased their target price on shares of BrainsWay from $10.00 to $11.00 and gave the stock an “outperform” rating in a research report on Thursday, May 9th.

BrainsWay Stock Performance

Shares of NASDAQ BWAY traded up $0.04 during trading hours on Friday, hitting $6.90. The stock had a trading volume of 39,051 shares, compared to its average volume of 93,647. The firm’s 50-day moving average price is $6.52 and its two-hundred day moving average price is $6.02. BrainsWay has a 52 week low of $2.50 and a 52 week high of $8.25. The company has a market capitalization of $114.99 million, a P/E ratio of -76.22 and a beta of 1.24.

BrainsWay (NASDAQ:BWAY) last issued its earnings results on Tuesday, August 6th. The company reported $0.04 EPS for the quarter. BrainsWay had a negative return on equity of 3.98% and a negative net margin of 4.83%. The firm had revenue of $10.01 million for the quarter, compared to the consensus estimate of $9.40 million. During the same quarter in the previous year, the company posted ($0.05) earnings per share.

Hedge Funds Weigh In On BrainsWay

A number of institutional investors have recently modified their holdings of BWAY. Tucker Asset Management LLC boosted its holdings in shares of BrainsWay by 1,686.9% during the 4th quarter. Tucker Asset Management LLC now owns 5,450 shares of the company’s stock worth $35,000 after buying an additional 5,145 shares during the period. Virtu Financial LLC bought a new stake in BrainsWay during the first quarter valued at about $60,000. Quadrature Capital Ltd acquired a new stake in shares of BrainsWay in the fourth quarter valued at about $70,000. Rhumbline Advisers grew its position in shares of BrainsWay by 10.3% in the second quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock valued at $110,000 after purchasing an additional 1,695 shares during the last quarter. Finally, Perritt Capital Management Inc bought a new position in shares of BrainsWay in the second quarter worth about $121,000. Institutional investors own 30.11% of the company’s stock.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.